# Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial

> **NCT07073469** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 330 (estimated)

## Conditions studied

- Stroke Ischemic

## Interventions

- **DRUG:** Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07073469
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073469, "Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07073469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*